DoD Prostate Cancer Biomarker Development Award | Apply Online

Opportunity Summary:

The DoD Prostate Cancer Biomarker Development Award (under the Congressionally Directed Medical Research Programs Prostate Cancer Research Program, or PCRP) is designed to push already-discovered prostate cancer biomarkers across the final hurdles needed for real clinical use. The program is responding to a long-standing gap in the field: many promising biomarkers have been reported over the past several decades, but very few have been validated or qualified in a way that convinces the broader medical community (or regulators) that they are reliable, reproducible, and meaningfully useful for patient care across more than one institution. Because PSA testing remains the dominant standard despite well-known limitations, this award targets near-term, high-impact studies that can credibly improve prostate cancer decision making in areas like identifying aggressive disease, predicting prognosis and progression, and predicting or assessing response to therapy. The intended end result is a biomarker (or set of biomarkers) that improves specificity for clinically significant cancer, helps separate aggressive from indolent disease, and ultimately reduces unnecessary biopsies and overtreatment while improving management for patients who truly need intervention.

A central feature of this opportunity is its strict focus on validation and qualification rather than discovery. Projects proposing to discover brand-new biomarkers, do early exploratory expression profiling, or refine biomarkers in model systems are considered outside the scope and will not be supported, mainly because they are unlikely to produce clinical impact in the near term. In this context, “validation” is framed as the analytical process of proving the biomarker or measurement technology can be assessed accurately and reliably, including establishing performance characteristics and reproducibility across conditions. “Qualification,” by contrast, is the evidence-based “fit for purpose” process demonstrating that the biomarker is meaningfully linked to biological processes and/or clinical endpoints. The program explicitly recognizes that modern prostate cancer care may require combinations of biomarkers, potentially mixing biofluid-based markers (blood or urine), tissue-based markers, and imaging approaches, with a strong emphasis on biomarkers that can be measured noninvasively or with minimal invasiveness. Examples mentioned include circulating tumor cells, genetic or epigenetic signatures, specific genes/proteins/metabolites, and molecular/physiological/immunological imaging entities.

Multi-institutional study design is not optional here; it is a defining requirement. The award expects large-scale efforts conducted across multiple institutions and, importantly, expects inclusion of independent patient cohorts rather than a single-institution dataset. This multi-site structure is meant to address the real-world problem that many biomarkers look promising in the lab where they were discovered but fail to generalize elsewhere. Applicants are also expected to take prostate tumor heterogeneity seriously, since molecular and clinical variation within and between tumors is a major reason biomarkers underperform. Strong applications should explain how heterogeneity could affect performance, how validation/qualification plans will account for it, and what that means for eventual clinical application.

The opportunity encourages applicants to leverage existing assets rather than rebuild infrastructure from scratch. That includes using established biorepositories, epidemiological cohorts, clinical databases/metadata, and existing transcriptomic or proteomic datasets, and it encourages collaboration with groups already connected to these resources (examples cited include the Prostate Cancer Biorepository Network and the North Carolina-Louisiana Prostate Cancer Project). Reviewers will be looking for evidence that specimens, data, and other materials are accessible and available so the work can start immediately after an award is made, reducing delays that often derail multi-site translational studies. The program also pushes applicants to show that the proposed work is not just scientifically sound but positioned for real-world uptake, with a stated expectation of high potential for commercialization and clinical use. Clinical trials are allowed when appropriate, consistent with the emphasis on getting to actionable clinical endpoints.

Applications must clearly describe the candidate biomarker(s) being advanced and are encouraged to evaluate multiple biomarkers rather than a single marker in isolation, reflecting the growing consensus that composite approaches often outperform single analytes. Applicants need to include preliminary data showing the biomarker is suitable for advancement, and then lay out a detailed approach for how feasibility, reliability, and reproducibility will be established. The award description highlights evaluation criteria that applicants should be prepared to address, such as performance improvements over existing clinical biomarkers, the presence of a robust analytical assay, evidence of biological association with disease state or aggressiveness, strength of association between biomarker change and clinical/pathological outcomes, and sufficient sensitivity and specificity to avoid detecting benign processes. Applicants are also pointed toward established frameworks and guidance, including the Tumor Marker Utility Grading System and relevant FDA guidance and processes around biomarker validation/qualification, with a strong recommendation to incorporate best practices from the marker-study design literature. Early communication with the FDA is encouraged so that FDA-driven milestones can be incorporated into the project plan.

Operationally, the award supports team science and formal coordination. A detailed implementation plan is expected, including critical milestones, translation-to-patient steps, and appropriate statistical expertise and statistical planning. Because these are multi-institutional projects, the application should also include a coordinated communication plan and leadership by experienced investigators who can manage complex, focused collaborative programs. The mechanism includes a “Partnering PI Option” that can support up to three PIs (an Initiating PI plus up to two Partnering PIs), each receiving a separate award, with the expectation that the combined effort is genuinely synergistic rather than loosely connected. The inclusion of external scientific advisors is encouraged, and the assigned PCRP Science Officer must be invited to periodic team meetings, reinforcing the cooperative and milestone-driven nature of the work.

For this specific funding announcement (W81XWH-13-PCRP-BDA), the instrument type is a cooperative agreement/grant through the Department of the Army (USAMRAA), with an estimated total funding level of $7.2 million and an expectation of about two awards. It is listed as unrestricted with respect to eligible applicant types (subject to any additional eligibility clarifications in the full text) and does not require cost sharing or matching. The opportunity was posted in mid-May 2013 with an application closing date of October 9, 2013, and it later archived in November 2013. As part of the review process, an oral presentation to the PCRP Integration Panel is required for applications that advance to the later stage of programmatic review, with presentations scheduled to be held in the National Capital Area (noted in the announcement as March 2014).

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: State and Regional Approaches to Improving Access to Services for Children and Youths with Epilepsy

Previous opportunity: State Planning Grants for Improving Services for Children and Youth with Autism Spectrum Disorder and other Developmental Disabilities

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 13 PCRP BDA

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 13 PCRP BDA) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 13 PCRP BDA", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.